{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:55:16Z","timestamp":1771656916526,"version":"3.50.1"},"reference-count":47,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Linkou Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CIRPG3H0061~2 and CORPG3J0151~2 to J.W-C.C.; CMRPG3J0971~3, CRRPG3K0021~2, NMRPG3K6201~3, CMRPG3K0601 to C-E.W.; CMRPG3F1911 to C.-Y. H."],"award-info":[{"award-number":["CIRPG3H0061~2 and CORPG3J0151~2 to J.W-C.C.; CMRPG3J0971~3, CRRPG3K0021~2, NMRPG3K6201~3, CMRPG3K0601 to C-E.W.; CMRPG3F1911 to C.-Y. H."]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). This study aimed to create a novel nomogram to help physicians suggest the optimal treatment for patients with EGFRm+ NSCLC. Records of 2190 patients with EGFRm+ NSCLC cancer who were treated with EGFR-TKIs (including gefitinib, erlotinib, and afatinib) at the branches of a hospital group between 2011 and 2018 were retrospectively reviewed. Their clinicopathological characteristics, clinical tumor response, progression-free survival (PFS), and overall survival (OS) data were collected. Univariate and multivariate analyses were performed to identify potential prognostic factors to create a nomogram for risk stratification. Univariate analysis identified 14 prognostic factors, and multivariate analysis confirmed the pretreatment independent factors, including Eastern Cooperative Oncology Group performance status, morphology, mutation, stage, EGFR-TKIs (gefitinib, erlotinib, or afatinib), and metastasis to liver, brain, bone, pleura, adrenal gland, and distant lymph nodes. Based on these factors, a novel nomogram was created and used to stratify the patients into five different risk groups for PFS and OS using recursive partitioning analysis. This risk stratification can provide additional information to clinicians and patients when determining the optimal therapeutic options for EGFRm+ NSCLC.<\/jats:p>","DOI":"10.3390\/cancers14040977","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:43:22Z","timestamp":1644965002000},"page":"977","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI"],"prefix":"10.3390","volume":"14","author":[{"given":"John Wen-Cheng","family":"Chang","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh-Fu","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-6357","authenticated-orcid":false,"given":"Ching-Fu","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-1027","authenticated-orcid":false,"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsi Scott","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Chih","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-En","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Santoni-Rugiu, E., Melchior, L.C., Urbanska, E.M., Jakobsen, J.N., Stricker, K., Grauslund, M., and S\u00f8rensen, J.B. (2019). Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers, 11.","DOI":"10.3390\/cancers11070923"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S1470-2045(17)30893-8","article-title":"Osimertinib improves progression-free survival in NSCLC","volume":"19","author":"Stirrups","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Canale, M., Petracci, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., and De Luigi, N. (2020). Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041047"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/JTO.0b013e3181cee47e","article-title":"De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer","volume":"5","author":"Takeda","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","article-title":"Chang Gung Research Database: A multi-institutional database consisting of original medical records","volume":"40","author":"Tsai","year":"2017","journal-title":"Biomed. J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wu, C.E., Chang, C.F., Huang, C.Y., Yang, C.T., Kuo, C.S., Hsu, P.C., and Chang, J.W. (2021). Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: A retrospective cohort study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08587-w"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1198\/106186006X133933","article-title":"Unbiased recursive partitioning: A conditional inference framework","volume":"15","author":"Hothorn","year":"2006","journal-title":"J. Comput. Graph. Stat."},{"key":"ref_21","first-page":"100085","article-title":"Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR\u2013Mutated Lung Cancer","volume":"1","author":"Haratake","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.21037\/jtd.2018.03.150","article-title":"The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: A literature-based pooled analysis","volume":"10","author":"Liang","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.2147\/CMAR.S253760","article-title":"Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors","volume":"12","author":"Chai","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3389\/fonc.2020.01481","article-title":"An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2017.07.002","article-title":"Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer","volume":"19","author":"Kawamura","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1002\/ijc.32025","article-title":"Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations","volume":"144","author":"Lin","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.4143\/crt.2017.512","article-title":"The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma","volume":"50","author":"Huang","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chang, Y.P., Chen, Y.M., Lai, C.H., Lin, C.Y., Fang, W.F., Huang, C.H., Li, S.H., Chen, H.C., Wang, C.C., and Lin, M.C. (2017). The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178676"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12967-015-0622-x","article-title":"Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis","volume":"13","author":"Castanon","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2217\/fon-2018-0469","article-title":"Peritoneal carcinomatosis in non-small-cell lung cancer: Retrospective multicentric analysis and literature review","volume":"15","author":"Abbate","year":"2019","journal-title":"Future Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1440-1843.2008.01268.x","article-title":"Peritoneal carcinomatosis in lung cancer","volume":"13","author":"Su","year":"2008","journal-title":"Respirology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijms.34739","article-title":"Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications","volume":"16","author":"Bianco","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1634\/theoncologist.2011-0385","article-title":"EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas","volume":"17","author":"Chen","year":"2012","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"680804","DOI":"10.3389\/fonc.2021.680804","article-title":"EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes","volume":"11","author":"Jin","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"24237","DOI":"10.18632\/oncotarget.24386","article-title":"Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations","volume":"9","author":"Tu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"viii526","DOI":"10.1093\/annonc\/mdy292.077","article-title":"Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC","volume":"29","author":"Ito","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1758835918797589","DOI":"10.1177\/1758835918797589","article-title":"Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer","volume":"10","author":"Su","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4143\/crt.2018.117","article-title":"Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4143\/crt.2013.120","article-title":"Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors","volume":"46","author":"Keam","year":"2014","journal-title":"Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.21037\/jtd-20-1587","article-title":"A nomogram for predicting brain metastases of EGFR-mutated lung adenocarcinoma patients and estimating the efficacy of therapeutic strategies","volume":"13","author":"Wang","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"567160","DOI":"10.3389\/fonc.2020.567160","article-title":"Value of 18F-FDG PET\/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"542957","DOI":"10.3389\/fonc.2020.542957","article-title":"CT Radiomics in Predicting EGFR Mutation in Non-small Cell Lung Cancer: A single Institutional Study","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation\u2013positive non\u2013small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2019.06.025","article-title":"(Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors","volume":"119","author":"Chang","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101994","DOI":"10.1016\/j.ctrv.2020.101994","article-title":"The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal","volume":"85","author":"Gristina","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100115","DOI":"10.1016\/j.esmoop.2021.100115","article-title":"A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903","volume":"6","author":"Ito","year":"2021","journal-title":"ESMO Open"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/977\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:20:16Z","timestamp":1760134816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14040977"],"URL":"https:\/\/doi.org\/10.3390\/cancers14040977","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}